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Tel Aviv, Israel; Antwerp, Belgium; Vancouver, British Columbia, and Montréal, Québec, Canada;
Cambridge, Massachusetts; and New Orleans, LouisianaObjectives This study sought to describe the pre-clinical evaluation of transapical mitral implantation
of the Tiara (Neovasc Inc, Vancouver, British Columbia, Canada) valve in preparation for ﬁrst-in-man
implantation.
Background The Tiara is a transcatheter self-expanding mitral bioprosthesis, speciﬁcally designed for
the complex anatomic conﬁguration of the mitral apparatus.
Methods Tiara valves were implanted in a short-term porcine model, in a long-term ovine model, and
in human cadavers.
Results Short-term and long-term evaluation demonstrated excellent function and alignment of the
valves, with no left ventricular outﬂow tract obstruction, coronary artery obstruction, or transvalvular
gradients. Long-term evaluation of 7 sheep demonstrated clinically stable animals. A mild degree of
prosthetic valve regurgitation was seen in 2 of the 7 sheep. A mild-to-moderate degree of paravalvular
leak, which was attributed to this animal model, was observed in 6 of these animals. Cardioscopy and
macroscopic evaluation demonstrated stable and secure positioning of the Tiara valve with no
evidence of injury to the ventricular or atrial walls. Pericardial leaﬂets were free and mobile without
calciﬁcations. Implantation of the Tiara valves in human cadaver hearts demonstrated, upon visual
inspection, proper anatomic alignment and seating of the valve, both at the atrial and at the
ventricular aspects of the native mitral apparatus.
Conclusions In preparation for the ﬁrst-in-man transcatheter mitral valve implantation, we report the
successful pre-clinical evaluation of the Tiara transcatheter self-expanding mitral bioprosthetic valve. In
porcine and ovine models without mitral regurgitation, transapical mitral implantation of the Tiara
valve is technically feasible and safe, and results in a stable and well-functioning mitral bioprosthesis.
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Abbreviations
and Acronyms
LV = left ventricle/ventricular
MR = mitral regurgitation
MV = mitral valve
PVL = paravalvular leak
TAMI = transapical mitral
implantation
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 7 , N O . 2 , 2 0 1 4 Banai et al.
F E B R U A R Y 2 0 1 4 : 1 5 4 – 6 2 Transapical Mitral Implantation of the Tiara
155Severe mitral regurgitation (MR) is commonly associated
with dilation of the heart and advanced coronary artery
disease, ultimately resulting in disability and death from
congestive heart failure. Although surgery remains the gold
standard treatment for MR, approximately one-third of
potential candidates are considered to be at too high risk for
surgical repair or replacement (1–3). Severe MR affects
approximately 2% of the population, but its prevalence
increases to 13.3% among patients 75 years of age or older in
industrialized countries. With advances in medicine
enhancing longer survival, the incidence of severe MR is
expected to rise dramatically (4).
Various novel percutaneous transcatheter valvular tech-
nologies have emerged as alternatives to open surgery for
high-risk patients (5). These technologies are classiﬁed
according to the part of the heart that is being targeted: the
leaﬂetsdpercutaneous leaﬂet plication, leaﬂet coaptation, or
radio-frequency leaﬂet ablation; the annulusdindirect
annuloplasty through the coronary sinus, or direct annulo-
plasty either true percutaneous or by a hybrid approach
through the left atrium; the chordaedpercutaneous chordal
implantation; or the left ventricle (LV)dpercutaneous LV
remodeling. The percutaneous edge-to-edge repair tech-
nology has been shown to be noninferior to open repair in
randomized clinical trials. However, percutaneous mitral
valve repair is not possible for many patients, and therefore,
mitral valve (MV) replacement may be an attractive alter-
native (5,6). Several transcatheter MV implantation tech-
nologies, either transapical or transseptal, are in various
stages of pre-clinical evaluation (7–9).
The Tiara (Neovasc Inc, Vancouver, British Columbia,
Canada) is a catheter-based self-expanding mitral bio-
prosthesis, speciﬁcally designed to ﬁt the complex anatomic
structure of the mitral apparatus. It is implanted using
a transapical approach. The valve assembly is shaped to
match the natural oriﬁce of the mitral valve and minimize
obstruction of the LV outﬂow tract (10). We describe here
the pre-clinical assessment of the Tiara valve in short-term
and long-term animal models, as well as in human cadaver
hearts, performed as part of the preparation for the planned
ﬁrst-in-man transapical mitral implantation (TAMI).
Methods
Valve properties. The Tiara bioprosthetic valve is fabricated
using cross-linked bovine pericardial tissue leaﬂets mounted
inside a self-expanding metal alloy frame and crimped onto
a short, ﬂexible 32-F delivery catheter for transapical delivery
(Fig. 1). A retractable sheath retains the valve in place until
deployment. The atrial portion engages the area of the left
atrium surrounding the mitral annulus, and a series of
anchoring structures actively engage the mitral leaﬂets and
chordae within the LV, securing the valve from retrograde
dislodgement during systole. During all stages of valveimplantation until the ﬁnal release and deployment, it is
possible to recapture the partially deployed valve and retrieve
it into the delivery catheter, reposition, and restart the
implantation process. Tiara implantation, orientation, and
alignment was performed under simultaneous echocardio-
graphic and ﬂuoroscopic guidance using a speciﬁc radi-
opaque set of markers on the nitinol frame and on the
delivery system.
Tiara implantation protocols. The animal protocols were
approved by the Montreal Heart Institute’s Animal Care
and Use Committee, and the animal care and use committee
of the Institute Mutualiste Montsouris Recherche, Paris,
France. The protocol for human cadaver trials was approved
by the Seattle Science Foundation, Seattle, Washington.
Transapical implantation of the Tiara bioprosthesis was
performed by a multidisciplinary team including 2 inter-
ventional cardiologists, a cardiac surgeon, and an echocar-
diographer, through a small subxyphoid incision. The atrial
portion of the Tiara (the atrial “skirt”) is deployed ﬁrst so
that the ﬂat aspect of the prosthesis frame is oriented
anteriorly to align with the D-shaped mitral annulus, fol-
lowed by deployment of the ventricular portion of the
prosthesis that anchors behind
the native anterior and posterior
mitral leaﬂets (Fig. 2).
Under general anesthesia and
mechanical ventilation, a small
subxyphoid incision (<5 cm) was
performed exposing the LV apex
to allow apical puncture. One
orthogonal U-shaped (purse
string) suture was placed around
the apical entry site. Unfractionated heparin (100 IU/kg)
and lidocaine (1 mg/kg) were administered intravenously
before apical cannulation. After apical puncture and sheath
insertion, a 6-F pigtail catheter and a J-tipped 0.035-inch
guide wire were inserted and then advanced across the mitral
apparatus into the left atrium. Following removal of the
pigtail catheter, the Tiara bioprosthesis, loaded in its delivery
system, was advanced over the guidewire and positioned in
the left atrium. Upon angiographic and echocardiographic
conﬁrmation of proper central positioning within the mitral
planes, the guidewire was removed. Tiara implantation
began with deployment of the atrial skirt to ﬁt the D-shaped
mitral annulus so that the ﬂat aspect of the prosthesis frame
was aligned with the LV outﬂow tract and the aorta.
Accurate alignment and engagement of the ﬂat aspect of the
Tiara bioprosthesis with the anterior side of the mitral
annulus was directed by echocardiography and guided by
ﬂuoroscopy utilizing special radiopaque markers on the
metal frame of the prosthetic valve. Once aligned and seated
on the atrial side of the mitral annulus, the ventricular
portion of the prosthesis was deployed and anchored behind
the native anterior and posterior mitral leaﬂets. Immediately
Figure 1. Tiara and Delivery System
Front and proﬁle views of the Tiara (upper panel). The D shape of the valve, the atrial “skirt” that engages the atrial aspect of the mitral annulus, and the
saddle-shaped valve are clearly seen. Transapical delivery system (lower panel).
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156following the ﬁnal launch of the Tiara, the delivery system
was removed, and hemostasis was secured with the previ-
ously placed apical purse string.
A ﬁnal echocardiographic, hemodynamic, and angio-
graphic evaluation was performed to document mitral
prosthesis function, valvular or paravalvular regurgitation,
aortic and tricuspid valve function, presence of an LV
outﬂow tract gradient, ventricular function, and patency of
the left coronary circulation.
Short-term animal model. The purpose of the short-term
model was to assess the safety and feasibility of Tiara
implantation, to test several implantation techniques, and to
make minor modiﬁcations and alterations in the design of
the prosthesis frame and delivery system. Healthy domestic
swine (mean weight 65 kg) were used, with a follow-up of
90 min to 96 h post-implantation. All animals with
a successful implantation were monitored hemodynamically
for a minimum of 90 min, at which time an echocardio-
graphic evaluation was performed. All but 7 animals were
euthanized immediately after the 90-min follow-up. These 7
animals were selected randomly from the pigs with no MR
or paravalvular leak (PVL). These animals that were allowed
to survive were extubated and allowed to recover fromanesthesia, and then monitored clinically for 4 to 96 h before
they were sacriﬁced. All hearts were explanted for macro-
scopic evaluation.
Long-term animal model. A normal ovine animal model
(mean weight 69 kg) was used to test and evaluate the long-
term performance of the implanted Tiara valve. The sheep
model is considered the gold standard for long-term testing
for valve implantation because the tissue leaﬂets are more
prone to calciﬁcation and destruction. The mitral annulus
size is comparable to an adult human and does not change
signiﬁcantly over the 5-month period compared with the
swine model. The dimensions of the Tiara bioprosthesis
used in this animal experiment were 29  35 mm.
Following successful implantation, the animals were
allowed to recover and then sent back to the farm. At
30 days (14 days), 90 days (14 days), and 120 days
(14 days), animals underwent follow-up evaluations
that included clinical assessment, tests for complete blood
count and chemistry, (including lactate dehydrogenase),
echocardiography and rotational cineangiography of the
heart to evaluate the positioning and function of the bio-
prosthesis and to detect fractures and deformations of the
frame of the Tiara.
Figure 2. Implantation Sequence of the Tiara
(A) The coronary sinus wire outlines the mitral valve annulus. The pigtail catheter is anteriorly positioned in the ascending aorta; the delivery system is through the
mitral annulus into the left atrium. (B) The atrial skirt is starting to open in the left atrium; the ﬂat aspect of the D-shaped Tiara is facing anteriorly. (C) The atrial skirt is
open and positioned on the atrial aspect of the mitral annulus, and the ventricular portion of the Tiara is delivered into position just before ﬁnal release. (D) Final
release of the Tiara, before removal of the delivery system.
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157Final evaluation was performed at 150  14 days post-
TAMI. Under general anesthesia, right and left heart
catheterization with hemodynamic evaluation was per-
formed followed by LV and aortic root angiography and left
coronary angiography. Immediately after catheterization, the
sternum was opened, and a transepicardial echocardiogram
was performed. Subsequently, the animals were euthanized,
and an in situ cardioscopy of the saline-ﬁlled heart was
performed. The Tiara valves were analyzed with high-quality
digital x-ray imaging (Faxitron MX-20, Faxitron Bioptics,
Tucson, Arizona) to detect microcalciﬁcation of the leaﬂets,
as well as fractures in the metal frame. Finally, the hearts
were harvested for macroscopic and microscopic evaluation.
Human cadaver model. Because of the substantial anatomic
differences between the healthy porcine and ovine hearts and
the diseased human heart with severe MR, the human
cadaveric model was used to test the suitability of the Tiara
bioprosthesis for the anatomy of the human heart. Even
though the Tiara was tested extensively and successfully in 2
different animal models, because it is intended eventually to
treat humans with severe MR and not healthy pigs or sheep,
it was important to test its ﬁttingness in this human model.
The cadaver model was used to test alignment, posi-
tioning, and anchoring of the Tiara valve in human cadaver
hearts. A total of 24 hearts were studied. The hearts usedwere freshly defrosted hearts without any ﬁxation, so the
valve leaﬂets were pliable.
Transapical implantations of the Tiara valves were per-
formed in both normal human hearts and in hearts of
patients with a history of severe MR, with and without LV
dilation, with and without aortic valve regurgitation.
Alignment of the Tiara in the native mitral apparatus and
the achievement of proper positioning and anchoring were
assessed using 2 endoscopic video cameras positioned in the
left atrium and in the LV of saline-ﬁlled hearts. The Tiara
valve implantation was performed using a pulsatile model
with manual stimulation to replicate ventricular contractions
and leaﬂet motion.
Results
Short-term animal model. During the time course of the
short-term animal model, minor alterations and variations of
the Tiara were tested, and the most suitable version of the
Tiara valve was used for the long-term animal model. The
results in part of the short-term animal experiments were
previously published (10).
Tiara valves were successfully implanted in 29 of the 36
(81%) animals. Implantation was unsuccessful in 7 animals
because of improper positioning of the valve (n ¼ 3), failure
Table 1. Echocardiographic Evaluation of the 7 Long-Term Animals, 150 Days Post-Tiara Implantation
Animal Heart Rhythm
PVL
(0–4)*
MR
(0–4)*
TR
(0–4)* LVOT Gradient
AR
(0–4)*
Pericardial Fluid
(0–3)y LVWMA
1 NSR 0 0 0 0 0 0 No
2 NSR 2 0 0 0 0 0 No
3 NSR 2 0 0 0 1 0 No
4 NSR 1 1 0 0 0 0 No
5 NSR 1 1 1 0 0 0 No
6 NSR 1 0 0 0 0 0 No
7 NSR 2 0 0 0 0 0 No
*Regurgitation severity: 0 ¼ trace/mild; 1 ¼mild; 2 ¼moderate; 3 ¼moderate to severe; 4 ¼ severe; yPericardial ﬂuid amount estimation: 0 ¼ none; 1 ¼
small; 2 ¼ moderate; 3 ¼ large/tamponade.
AR ¼ aortic regurgitation; LVOT ¼ left ventricular outﬂow tract; LVWMA ¼ left ventricular wall motion abnormality; MR ¼ mitral regurgitation;
NSR ¼ normal sinus rhythm; PVL ¼ paravalvular leak; TR ¼ tricuspid regurgitation.
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158of the valve anchors to properly engage during deployment
(n ¼ 2), and ventricular ﬁbrillation (n ¼ 2). The total
procedure time from thoracotomy to prosthesis deployment
ranged from 17 to 26 min. The implantation time from
apical access to closure ranged from 5 to 13 min. None of
the valves migrated or embolized during or after implanta-
tion. There was an evolution and reﬁnement of the
implantation procedure and of the device over the course of
these 36 animals. There was a steady increase in the rate of
successful implantations as the series progressed, with the
ﬁnal 12 animals in the series all undergoing a successful and
uneventful implantation.
All of the 29 animals that underwent a successful Tiara
implantation remained hemodynamically stable throughout
the procedure. Self-limited bouts of atrial ﬁbrillation were
occasionally noted when the valve was manipulated within
the left atrium, but no sustained or hemodynamically
relevant arrhythmias occurred after implantation. Post-
procedural cardiac catheterization in these animals demon-
strated widely patent circumﬂex coronary arteries and no
discernible LV outﬂow tract gradient. Transesophageal
echocardiography conﬁrmed good function and alignment
of all valves and leaﬂets, with no LV outﬂow tract ob-
struction, encroachment on the aortic valve, or transvalvular
gradients. A signiﬁcant PVL was only present in animals
showing a mismatch between the MV annulus size and the
prosthesis diameters. None of the last 8 animals had any
signiﬁcant PVL. Macroscopic evaluation of the explanted
hearts demonstrated stable and secure positioning of the
prostheses in both vertical and horizontal planes of the
mitral annulus, without evidence of traumatic injuries to
the ventricular or the atrial walls.
Long-term animal model. Seven animals were evaluated 150
 14 days post-Tiara implantation. A summary of the long-
term echocardiographic and hemodynamic evaluation is
presented in Table 1. All 7 animals had been clinically
stable, maintaining sinus rhythm and normal behavior
throughout the follow-up, without signs of cardiovasculardecompensation. Echocardiographic assessment demon-
strated that all Tiara bioprostheses were well positioned,
properly aligned with the ﬂat aspect of the D-shape facing
the aorta, with excellent leaﬂet motion and coaptation
(Fig. 3). Five of the 7 animals had no MR through the
prosthetic valve, and 2 had a mild degree of valvular MR. Six
of the 7 animals had a mild or moderate PVL, and 1 animal
had no PVL (Table 1). None of the animals developed
a signiﬁcant pressure gradient across the mitral prosthesis or
in the LV outﬂow tract and the aortic valve, and none
developed elevated pulmonary pressure or tricuspid valve
regurgitation. None had pericardial ﬂuid accumulation.
Angiographically, all of the bioprostheses were properly
positioned and secured. Five animals had a mild or moderate
degree of MR (valvular and paravalvular), and 2 had none
(Table 2). Coronary angiography at 150 days post-TAMI
revealed patent coronary arteries without impingement on
the circumﬂex coronary artery (Fig. 4), normal LV size and
function, and normal pulmonary artery and right-side
pressures. Aortic root angiography ruled out the presence of
aortic valve regurgitation in all animals.
The degree of PVL in all long-term animals was such that
it did not have any hemodynamic signiﬁcance, and also, it
did not cause any degree of hemolysis, as assessed by the
complete blood counts and lactate dehydrogenase levels at
follow-up compared with the baseline levels.
As only 1 size of Tiara valve was available for implanta-
tion, it is thought that the PVL observed is attributable to
the size mismatch between the native annulus and prosthetic
device. In all animals, LV wall motion and overall function
were normal. High-quality digital x-ray imaging (Faxitron
MX-20) did not reveal any deformations of the metal frame
struts.
In situ cardioscopy showed homogeneous coverage of the
metal struts with a white ﬁbrotic connective tissue layer,
both along the atrial and ventricular struts. Positioning of
the prosthesis was stable and secure, both in the vertical and
horizontal planes of the mitral annulus, without evidence of
Figure 3. Three-Dimensional Echocardiogram of the Implanted Tiara 150-Days Post-Implantation
The D shape of the Tiara is clearly seen. (Left) The Tiara is closed during systole, and the 3 leaﬂets are seen. (Right) Tiara is open during diastole, and the native aortic
valve is closed.
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159traumatic injuries to the ventricular or the atrial walls. The
prosthesis leaﬂets were freely mobile, supple, and without
evidence of ﬁbrous deposits, clots, or calciﬁcations.
Macroscopic and microscopic evaluation demonstrated
that the devices appeared well seated; all valve frames
showed good incorporation by a thin pannus around the
atrial and ventricular surfaces with ﬁbrous tissue growth
adequate for healing. The pannus was composed of dense,
well-organized smooth muscle cells/ﬁbroblasts in a collage-
nous matrix around the device components. The pericardial
leaﬂets were intact without tears or perforations. There was
no evidence of endocarditis or leaﬂet calciﬁcation, and the
myocardium adjacent to the device showed mild compres-
sion in some areas without necrosis or signiﬁcant inﬂam-
mation (Figs. 5 and 6).Table 2. Cardiac Catheterization Evaluation of the 7 Long
Cardiac Catheterization
Animal
MR
(0–4)*
Coronary Artery
Obstruction
AR
(0–4)* LVOT
1 0 No 0
2 1 No 0
3 0 No 0
4 2 No 0
5 2 No 0
6 2 No 0
7 2 No 0
*Regurgitation severity: 0 ¼ trace/mild; 1 ¼ mild; 2 ¼ moderate; 3 ¼ mo
LV ¼ left ventricular; other abbreviations as in Table 1.Human cadaver implantation. A total of 24 hearts were
studied, 17 female hearts and 7 male hearts; the age range
was 58 to 94 years, body weight range was 36 to 87 kg (mean
62 kg), and body height range was 122 to 183 cm (mean
160 cm). Twelve hearts had moderate or severe mitral
regurgitation, 7 hearts had congestive heart failure, and 5
were normal hearts. Transapical implantation of Tiara
valves was performed under direct visual guidance using
ventricular and atrial endoscopic video cameras in saline-
ﬁlled hearts. Proper orientation of the asymmetric atrial
portion of the Tiara valve as well as appropriate engagement
and position of the ventricular anchoring system were
conﬁrmed ﬁrst by direct vision on video monitor screens and
later by macroscopic evaluation after dissection of the left
atrial wall and opening the LV wall. The implantation-Term Animals, 150 Days Post-Tiara Implantation
Digital X-Ray
Gradient LV Function
Valve Deformation or
Signiﬁcant Frame Fracture
0 Good No
0 Good No
0 Good No
0 Good No
0 Good No
0 Good No
0 Good No
derate to severe; 4 ¼ severe.
Figure 4. Coronary Angiography and Left Ventriculography 150 Days Post-Tiara Implantation
(Left) Patent coronary arteries, without evidence of impingement or obstruction of the left circumﬂex coronary artery, are shown. (Right) Left ventriculography in
a sheep 150 days following transapical mitral implantation (TAMI).
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160resulted in appropriate geometric positioning with full
circumferential coverage of the atrial aspect of the mitral
annulus and proper orientation of the D shape (Fig. 7), and
good apposition and location of the ventricular anchoring
system. Orientation, alignment, and stable anchoring were
achieved both in normal hearts and in dilated hearts with
heart failure or MR.Figure 5. Ventricular View of the Tiara 150 Days After Implantation in
a Sheep’s Heart
The papillary muscles (held by clamps), chordae tendineae, and the
subvalvular mitral apparatus are intact. Valve frames are covered with ﬁbrous
tissue growth adequate for healing. Pericardial leaﬂets are intact without tears
or perforations, there was no evidence of endocarditis or leaﬂet calciﬁcation,
and the myocardium adjacent to the device is intact.Discussion
The pre-clinical assessment of the safety and feasibility of
implantation of the Tiara transcatheter bioprosthetic mitral
valve, including the short-term and long-term performance,
was successful.
Using the porcine short-term animal model, we have
conﬁrmed the feasibility and short-term safety of Tiara
implantation. In addition, we have developed a rapid and
straightforward implantation procedure resulting in a stable
and well-aligned functional bioprosthesis. Macroscopic
evaluation of the explanted hearts demonstrated stable and
secured positioning of the valves in all planes of the mitral
apparatus, without evidence of traumatic injuries to the
ventricular or the atrial wall. These short-term results were
encouraging and paved the way for long-term animal model
experiments and subsequent human cadaver implantations.
At 150 days after Tiara implantation, all 7 long-term
animals exhibited normal clinical status and behavior without
any signs of heart failure. There was no signiﬁcant MR
observed, and the LV function was normal in all. The metal
frames were homogeneously covered with a ﬁbrous tissue on
both sides of the mitral annulus, suggesting proper healing
without any visible signs of inﬂammation. The concerns
regarding potential long-term deterioration of prosthesis
functionality and integrity were answered as no deformation
of the metal frame was seen, the prosthesis leaﬂets were
mobile and free of clots, and there was no macro- or
microcalciﬁcation up to 150 days post-implantation.
Transcatheter MV implantation has the potential to
become the preferred intervention to treat severe MR in
patients who are at high risk for surgery, because it can
theoretically reduce MR to an extent similar to that of
Figure 6. Atrial View of the Tiara 150 Days After Implantation
in a Sheep’s Heart
Picture was taken after the atrial wall was removed. The atrial skirt of the Tiara
is well seated on the atrial aspect of the mitral annulus. Valve frames are
covered with ﬁbrous tissue growth adequate for healing. Pericardial leaﬂets
are intact without tears or perforations; there was no evidence of endocarditis
or leaﬂet calciﬁcation. The adjacent atrial wall is intact and free of inﬂam-
mation or necrosis.
Figure 7. Atrial View of the Tiara Implanted in a Human Cadaver Heart
With a History of Severe MR
The atrial skirt of the Tiara is well seated in the atrial aspect of the mitral
annulus. The Tiara is aligned so that the ﬂat aspect of the D-shaped Tiara is
properly facing the aortic-mitral curtain.
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161surgery while preserving the mitral apparatus. However,
many challenges need to be addressed in the design and
development of a device to be deployed across an asymmetric
and multi-planar MV annulus. The ideal device must be
stable and resistant to displacement or migration while
enduring continuous cyclical movements of the mitral
annulus and the base of the heart, as well as the high
pressure gradients that are generated across the mitral valve.
Valve materials must be durable enough to withstand the
loads generated. Because regurgitation is poorly tolerated in
the mitral position, valvular regurgitation and PVL after the
implantation must be minimized. Additionally, the valve
must not obstruct the LV outﬂow tract, occlude the
circumﬂex coronary artery, or compress the coronary sinus.
Ideally, the valve should minimize conduction system
disruption. Transcatheter MV implants should restore
unidirectional ﬂow, spare chordal structures, and leave
adjacent myocardium intact while minimizing the risks
associated with the procedure, allowing high-risk patients
and those who are not candidates for surgery to receive
deﬁnitive treatment.
The Tiara is a catheter-based mitral valve bioprosthesis
intended for the treatment of patients with symptomatic
severe MR who are not candidates for mitral valve surgery.
The Tiara utilizes cross-linked bovine pericardial tissue
leaﬂets mounted inside a self-expanding metal alloy frame
and crimped onto a short, ﬂexible 32-F delivery catheter for
transapical delivery. The tricuspid bioprosthetic Tiara wasspeciﬁcally designed to ﬁt the complex anatomic structure of
the mitral apparatus. It ﬁts the area of the left atrium
surrounding the mitral annulus and engages the mitral
leaﬂets and chordae within the LV so it is secured from
anterograde or retrograde dislodgement. The assembly of
the Tiara valve is shaped to match the natural oriﬁce of the
MV and to avoid post-implantation impingement on the
LV outﬂow tract and on the coronary blood vessels.
On the basis of our short-term and long-term animal
results and our early human ex vivo experiments, we have
demonstrated that the Tiara frame geometrically ﬁts the
anatomy and shape of the native mitral annulus without
impinging on the LV outﬂow tract or circumﬂex artery. Due
to its self-expanding properties, the PVL observed should
be minimized with proper annulus–prosthesis match.
The device is well anchored, yet maintains the functional
complexity and integrity of the subvalvular apparatus, which
is an important characteristic of myocardial contractility,
especially in patients with reduced ejection fraction and
decreased contractility.
Study limitations. The Tiara valve is a prototype, and there
are limitations inherent to this proof-of-concept study. First,
the Tiara was designed and built to ﬁt human hearts with
severe MR. Tiara has not been tested in a long-term MR
model where both the left atrium and ventricle are dilated.
Testing it in the hypercontractile normal sheep heart with
a small LV and small left atrium is problematic because the
anatomy and behavior of the model is different from that of
the intended target. No doubt that for human implantation
more advanced imaging modalities will be used to better
guide the TAMI procedures. These advanced imaging
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162modalities will include online Doppler and 3-dimensional
transesophageal echocardiography, as well as 3-dimensional/
4-dimensional computed tomography angiography.
Second, the Tiara was available in 1 annular size, and
native annulus–prosthesis mismatch could not be avoided in
some cases, despite tight criteria for animal selection. These
2 major limitations are the cause of the mild-to-moderate
degree of PVL observed. Finally, because Tiara is a self-
expanding valve, it is unknown how the system will behave
in a partially or severely calciﬁed mitral apparatus. In-
complete prosthesis apposition against the myocardial
structures is known to cause PVL with transcatheter aortic
valve implantation. A similar situation remains possible with
the Tiara valve, which calls for careful selection of clinical
cases for the initial human clinical trials.
Conclusions
The Tiara is a catheter-based MV bioprosthesis intended for
the treatment of patients with symptomatic severe MR who
are high surgical risk candidates for open MV surgery. The
results of our short-term and long-term pre-clinical experi-
mentation with the Tiara transcatheter self-expanding mitral
bioprosthetic valve are encouraging. We have demonstrated
that the implantation of the Tiara valve in healthy swine and
sheep is feasible and safe. Tiara implantation resulted in
a stable and well-functioning MV bioprosthesis, for up to
150 days of follow-up. The durability, functionality, leaﬂet
pliability, and lack of leaﬂet calciﬁcation, as well as tissue
coverage of the metal frame, were all veriﬁed in the long-
term animal experiments. The results of the on-going
pre-clinical experiments of the Tiara valve will hopefully lead
the way to human clinical trials.Reprint requests and correspondence: Dr. Shmuel Banai,
Interventional Cardiology, Tel Aviv Medical Center, 6 Weizman
Street, Tel Aviv 64239, Israel. E-mail: shmuelb@tlvmc.gov.il.REFERENCES
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